Quick Takeaways
- Matrix Capital Management Company, LP filed SCHEDULE 13G for Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE).
- Disclosed ownership: 5.7%.
- Date of event: 31 Mar 2025.
Matrix Capital Management Company, LP - 31 Mar 2025 SCHEDULE 13G Report for Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE)
- Filing Manager
- Matrix Capital Management Company, LP
- Reporting Manager
- Matrix Capital Management Company, LP
- Symbol
- MAZE
- Shares outstanding
- 43,617,263 shares
- Disclosed Ownership
- 2,486,184 shares
- Ownership
- 5.7%
- Form type
- SCHEDULE 13G
- Filing time
- 14 May 2025, 16:10:14 UTC
- Date of event
- 31 Mar 2025
- Next filing
- 13 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Matrix Capital Management Company, LP disclosed 5.7% ownership in Maze Therapeutics, Inc. Common Stock, $0.001 par value per share (MAZE) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 May 2025, 16:10.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 5.7% | 2,486,184 | 0 | 2,486,184 | /s/ David E. Goel | David E. Goel, Managing General Partner | |
| David E. Goel | 5.7% | 2,486,184 | 0 | 2,486,184 | /s/ David E. Goel | David E. Goel, individually |